Claims

1. Use of Aa CD89-activating molecule ~~for use~~ in the manufacture of a medicament for inducing apoptosis in neutrophils.

2. The ~~CD89-activating molecule~~use of claim 1, wherein ~~it is a~~the CD89-activating molecule comprises~~ing~~ Fc-alpha or a functional equivalent thereof.

3. The ~~molecule~~use of claim 2, wherein ~~it~~the CD89-activating molecule is immunoglobulin A (IgA).

4. The ~~IgA~~use of claim 3, wherein the IgA is derived from serum or plasma.

5. The ~~IgA~~use of claim 3 or claim 4, wherein the IgA is dimeric.

6. The ~~IgA~~use of claim 3 or claim 4, wherein the IgA is monomeric.

7. The ~~IgA~~use of claim 5, wherein the IgA dimer comprises a J-chain.

8. The ~~IgA~~use of claim 7, wherein the IgA dimer comprises a secretory component.

9. The ~~IgA~~use of claim 3 or claim 4, wherein the IgA comprises monomeric and dimeric IgA.

10. The ~~IgA~~use of any of claims 3 to 9, ~~which~~wherein the IgA is polyclonal.

11. The ~~IgA~~use of any of claims 3 or 5 to 9, ~~which~~wherein the IgA is monoclonal.

12. The ~~IgA~~use of any of claims 3 to 11, wherein the IgA is IgA1 or IgA2 or a mixture thereof.

13. The use~~CD89-activating molecule~~ of claim 1, wherein ~~it~~the CD89-activating molecule is an anti-CD89 antibody, preferably a monoclonal antibody.

14. A pharmaceutical composition comprising ~~the~~a CD89-activating molecule ~~of~~referred to in any of claims 1 to 13, wherein at least 50% of ~~the~~ protein in the composition is the CD89-activating molecule.

15. The ~~CD89-activating molecule~~use of any of claims 1 to 13, wherein the neutrophils are comprised in a patient with an autoimmune disorder or inflammatory condition.

16. The ~~CD89-activating molecule~~use of claim 15, wherein the autoimmune disorder or inflammatory condition is selected from sterile neutrophilic inflammation, infectious inflammation, neutrophil-induced inflammation, inflammatory bowel disease and NETosis.

17. The ~~CD89-activating molecule~~use of claim 15, wherein the autoimmune disorder is arthritis, in particular rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis/Morbus Bechterew, or reactive arthritis.

18. The ~~CD89-activating molecule~~use according to any of claims 1 to 13, wherein the ~~CD89-activating molecule~~medicament is formulated for local administration ~~administered locally~~.

19. The ~~CD89-activating molecule~~use according to any of claims 1 to 13, wherein the neutrophils are in a patient with cystic fibrosis.

~~20. Method for inducing apoptosis of neutrophils, comprising bringing the neutrophils in contact with an effective dose of the CD89-activating molecule of any of claims 1 to 13.~~

~~21.~~20. The ~~method~~use of claim ~~20~~1, wherein the neutrophils have been pre-activated by an inflammatory stimulus such as inflammatory cytokines or microbial components (e.g. LPS).